By Marleen Kaesebier<\/p>\n
ZURICH, April 3 (Reuters) – U.S. President Donald Trump’s 100% tariffs on the pharmaceutical industry threaten global production, \u200csupply chains and ultimately will harm patients, Switzerland’s pharmaceutical \u200cassociation interpharma said on Friday.<\/p>\n
It urged the Swiss government to negotiate a similar \u200bdeal to that finalised by Britain, which the UK government said on Thursday made Britain the only country to have tariff-free access to the U.S. pharmaceutical market following Trump’s executive order.<\/p>\n
“The tariffs imposed \u200cby the U.S. threaten \u2060global production and supply chains for pharmaceuticals, hinder research and development, and ultimately harm patients worldwide,” interpharma \u2060said in a statement posted to LinkedIn.<\/p>\n
Under Trump’s order signed on Thursday, branded pharmaceuticals imported into the U.S. will be subject to \u200bthe tariffs \u200bunless manufacturers agree to government \u200bdrug pricing deals or commit \u200cto making their products domestically.<\/p>\n
The British government’s deal on tariff-free access for UK-made medicines agrees to higher prices for new drugs, including those purchased by Britain’s National Health Service.<\/p>\n
“We call on Switzerland to advocate for a solution on par with that of the \u200cUnited Kingdom in its tariff negotiations \u200bwith the U.S.. The goal must \u200bbe to free the \u200bpharmaceutical industry from tariffs as much as possible,” interpharma \u200csaid.<\/p>\n
Chemical and pharmaceutical products made \u200bup more than \u200bhalf of Switzerland’s total exports in 2025, which hit a record 287 billion Swiss francs ($359.02 billion). Excluding gold, other precious \u200bmetals, gems, artworks \u200cand antiques, Swiss exports to the U.S. specifically were \u200bworth 54.7 billion Swiss francs.<\/p>\n
($1 = 0.7994 Swiss francs)<\/p>\n
(Reporting by Marleen \u200bKaesebier; editing by Barbara Lewis)<\/p>\n","protected":false},"excerpt":{"rendered":"By Marleen Kaesebier ZURICH, April 3 (Reuters) – U.S. President Donald Trump’s 100% tariffs on the pharmaceutical industry…\n","protected":false},"author":2,"featured_media":44039,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[18,25415,4587,2833,41,276,906,17,112],"class_list":{"0":"post-44038","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-switzerland","8":"tag-donald-trump","9":"tag-global-production","10":"tag-pharmaceutical-industry","11":"tag-supply-chains","12":"tag-swiss","13":"tag-swiss-francs","14":"tag-swiss-government","15":"tag-switzerland","16":"tag-tariffs"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116341978110524588","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/44038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=44038"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/44038\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/44039"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=44038"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=44038"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=44038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}